Our Research DollarsWebuadmin2019-06-06T17:27:05+00:00
Our Research Dollars
$150,000 – Dr. Ismael J Samudio, Ph.D – The University of Texas MD Anderson Cancer Center: Overcoming stromal-mediated drug resistance cells: the role of fatty acid metabolism in the Warburg effect
$150,000 – Dr. Jennifer Carew, Ph.D & Dr. Frank Giles, Ph.D – UT Health Science Center at San Antonio: Aurora A: A Novel Therapeutic Target for Imatinib, Desatinib, Nilotininb and Bosutinib-Resistant Chronic Myeloid Leukemia and Ph Acute Lymphoblastic Leukemia
$150,000 – Dr. Pier Paolo Scaglioni, Ph.D. – The University of Texas Southwestern Medical Center: Development of a novel targeted therapy for acute and chronic leukemias
$191,530 – Alex W. Tong, Ph.D. and Marvin J. Stone, M.D. – Baylor Research Institute: Development of a Cancer Cell Vaccine for Treatment of Multiple Myeloma and Plasma Cell Leukemia. This new study utilized translation studies to explore developing a cancer cell vaccine as a new treatment for Plasma Cell Leukemia and Multiple Myeloma.
$300,000 – Vikas Bhushan, M.D. – The University of Texas Southwestern Medical Center: Allodepleted T-Cell Infusions in Patients Receiving Nonmyeloablative Hematopoietic Stem Cell Transplants. This new study gathered allogeneic hematopoietic cell transplantation data and utilized selective allodepletion to decrease graft vs host disease.
$362,861 – Edward D. Agura, M.D. and Douglas H. Smith, M.D., Ph.D. – Baylor Research Institute: The Effect of HLA Mismatches on the Outcome of Unrelated Donor-Bone Marrow Transplants in the Treatment of Leukemia and Lymphoma. This study has resulted in an improved allogeneic bone marrow transplant process while reducing immunologic complications due to imperfect tissue matching.
$225,000 – Robert Collins, M.D. – The University of Texas Southwestern Medical Center: The Study of Mechanisms of Graft vs Host Disease Using Quantitative Assay of Antigen-Specific T Cells. This study applied to all types of leukemia and has produced a completely new and improved treatment methodology for allogeneic stem cell transplantations.
$25,000 – Dr. Alan Miller – Baylor Scott & White Health: To identify a bio marker that is cost effective and minimally invasive for monitoring AML, the response to therapy, and progression to treatments in up to 100 patients across Texas to improve the survival rates.
$15,000 – UT Southwestern Medical Center – Proceeds from the inaugural Dance for Reagan event in honor of Reagan McDonald and her courageous battle with leukemia.
$80,000 – Dr. Premal Lulla – Baylor College of Medicine, Center for Cell & Gene Therapy: The study of adoptively transferred leukemia antigen-specific T-cells as treatment for Acute Myeloid Leukemia relapse after an allogenic hematopoietic stem cell transplant.
$20,000 – Dr. Courtney DiNardo – The University of Texas MD Anderson Cancer Center: Study of D2HG Levels in AML Patients with IDH1/2 Mutations.
$20,000 – Dr. Philip Thompson – The University of Texas MD Anderson Cancer Center: Identifying Immunologic Predictors of Response and Resistance to Blinotumomab Therapy in Pre-B cell ALL.
$20,000 – Dr. Paul Trippier – Texas Tech University Health Sciences Center: Development of AKR1C# Inhibitors for the Treatment of Leukemia.
$100,000 – Dr. Maro Ohanian – The University of Texas MD Anderson Cancer Center: Detoxifying the Bone Marrow Microenvironment with Acute Myeloid Leukemia (AML) in Texas.
$10,000 – Dr. Stephen Mathew – The University of North Texas Health Science Center: Evaluating NK Cell Receptor CS1 as a Novel Biomarker and an Immunotherapy Target for Pediatric Acute Lymphoblastic Leukemia
$10,000 – Dr. Christopher Benton – The University of Texas MD Anderson Cancer Center: The Assessment of Large Numbers of Patient-Specific Acute Myeloid Leukemia (AML) Cells at the Single-Cell Level for Multiple AML Specific Mutations Using Flow Cytometry
$10,000 – Dr. Rayne Rouce – Baylor College of Medicine, Center for Cell & Gene Therapy, Texas Children’s Cancer Center, and Houston Methodist Hospital: Virus-specific T cells with Tumor-Specificity for Treatment of Relapse and Viral Infection After Bone Marrow Transplant
$10,000 – Dr. Xin Long – Baylor College of Medicine, Texas Children’s Cancer Center: Reducing Stroma-Induced Chemotherapy Resistance in Pediatric AML by Inhibition of MEK1/2-ERK1/2 Pathway
$10,000 – Peter Ruvolo, PhD – The University of Texas MD Anderson Cancer Center: “Elucidating Galectin 3 role in survival pathways in a newly identified At Risk AML patient population”
$10,000 – Koji Sasaki, MD– The University of Texas MD Anderson Cancer Center: “Clinical Application of Artificial Intelligence in Patients with Acute Leukemia”
$10,000 – Ghayas C. Issa, MD – The University of Texas MD Anderson Cancer Center: “Investigating the Expression of the Luteinizing Hormone Receptor in the Hematopoietic Stem Cells of Patients with Leukemia”
$10,000 – Sean M. Post, PhD – The University of Texas MD Anderson Cancer Center: “Development of personalized therapies and novel compounds for hnRNP K/c-Myc-driven leukemias”
$10,000 – Sangram Raut, PhD– University of North Texas Health Science Center: “Lipoprotein Based Multi-agent Targeted Therapy for AML”
$100,000 – Jian Xu, PhD – The University of Texas Southwestern Medical Center: “Comprehensive Analysis of Structural Variants in AML by Combining Next-Generation Optical Genome Mapping and Sequencing”
$100,000 – Kapil Bhalla, MD and Courtney DiNardo, MD – The University of Texas MD Anderson Cancer Center: “Targeted therapy for AML expressing somatic or germline mutant RUNX1″